Last €4.13 EUR
Change Today +0.097 / 2.41%
Volume 0.0
QLT On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ GS
Frankfurt
As of 2:04 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

qlt inc (QLT) Snapshot

Open
€4.13
Previous Close
€4.03
Day High
€4.13
Day Low
€4.11
52 Week High
06/28/13 - €5.44
52 Week Low
08/15/13 - €2.97
Market Cap
210.7M
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
51.1M
EX-Date
06/28/13
P/E TM
--
Dividend
--
Dividend Yield
71.14%
Current Stock Chart for QLT INC (QLT)

Related News

No related news articles were found.

qlt inc (QLT) Related Businessweek News

No Related Businessweek News Found

qlt inc (QLT) Details

QLT Inc., a biotechnology company, develops and commercializes ocular products that address the unmet medical needs of patients and clinicians worldwide. It focuses on the development of QLT091001, a synthetic retinoid compound, which is in phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and phase IIa clinical trials for the treatment of impaired dark adaptation. The company was founded in 1981 and is headquartered in Vancouver, Canada.

37 Employees
Last Reported Date: 02/28/14
Founded in 1981

qlt inc (QLT) Top Compensated Officers

Chief Financial Officer and Principal Account...
Total Annual Compensation: $182.9K
Senior Vice President of Business Development...
Total Annual Compensation: $320.6K
Compensation as of Fiscal Year 2012.

qlt inc (QLT) Key Developments

QLT Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

QLT Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported net loss and comprehensive loss of $4,849,000 or $0.10 per basic and diluted share, loss from continuing operations was $5,700,000 or $0.11 per basic and diluted share, operating loss was $6,643,000, loss from continuing operations before income taxes was $5,535,000 against net loss and comprehensive loss of $9,181,000 or $0.18 per basic and diluted share, loss from continuing operations was $8,163,000 or $0.16 per basic and diluted share, operating loss was $10,077,000, loss from continuing operations before income taxes was $8,163,000 a year ago. The improvement in loss per share from continuing operations was primarily due to higher restructuring charges recorded in 2012 and savings related to the company's 2012 restructuring initiatives. For the full year, the company reported net loss and comprehensive loss of $24,871,000 or $0.49 per basic and diluted share, loss from continuing operations was $25,838,000 or $0.51 per basic and diluted share, operating loss was $28,490,000, loss from continuing operations before income taxes was $25,239,000 against net income and comprehensive income of $45,698,000 or $0.91 per basic and diluted share, loss from continuing operations was $42,264,000 or $0.84 per basic and diluted share, operating loss was $54,675,000, loss from continuing operations before income taxes was $46,164,000 a year ago. The improvement in operating results in comparison to the same periods in 2012, are primarily due to savings related to the company's 2012 restructuring initiatives and restructuring charges recorded in 2012.

QLT Inc. Announces Positive Preliminary Results from Phase 1b Retreatment Trial of QLT091001 in Subjects with Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65

QLT Inc. announced positive preliminary results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT). Preliminary results of this Phase 1b study showed clinically meaningful improvements in visual fields (VF) and visual acuity (VA). To date, 19 of 27 subjects (70%) had an increase in VF retinal area from baseline of >= 20% in at least 1 eye at 2 consecutive visits within 6 months from the start of any QLT091001 treatment course. In addition, 70% of subjects had an increase in VA from baseline of >= 5 letters in at least 1 eye at 2 consecutive visits within 6 months from the start of any treatment course. The percentage of VF and VA responders identified by disease and mutation. Dosing in the study is now completed and subject follow-up is ongoing. The final clinical data, including duration of response and other evaluations, are anticipated for release in the third quarter of 2014. This multicenter, open-label Phase 1b proof-of-concept trial was an extension study in which LCA or RP subjects with RPE65 or LRAT mutations who had been previously treated with a single course of QLT091001 in the company's previously completed Phase Ib study, received up to three 7-day courses of QLT091001 to assess visual outcomes and safety following retreatment. VF was assessed using Goldmann Visual Field (GVF) and VA was assessed using best-corrected visual acuity (BCVA) at baseline and days 7, 14, 30 and 60 after each treatment course, then bimonthly until the next treatment course. Safety assessments included complete ophthalmic and physical examinations, electroretinograms (ERGs), optical coherence tomography (OCT) retinal architecture, electrocardiograms, laboratory testing and reported adverse events. Subjects received treatment with QLT091001 at doses of 10, 40 or 60 mg/m(2), with the majority of subjects receiving 40 mg/m(2). Retreatment was initially determined based on established retreatment criteria or at Investigator discretion. This was later amended to allow retreatment to occur as early as 30 days but no later than 60 days after a previous treatment course to maintain dosing within a fixed interval. For these reasons, the time between each treatment course in this trial varied between subjects for each course and also varied between courses for each subject (1-13 months). There was also a wide range in time (7-32 months) per subject that elapsed between the single course treatment in the previously completed Phase Ib trial and treatment in this trial. All adverse events reported in this trial were consistent with the retinoid class of medications and were transient and/or reversible. Only one serious adverse drug reaction (intracranial hypertension (ICH), a known class effect of retinoids), was reported in the study and it was resolved.

QLT Inc.(NasdaqGS:QLTI) dropped from NASDAQ Biotechnology Index

QLT Inc. will be removed from NASDAQ Biotechnology Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QLT:GR €4.13 EUR +0.097

QLT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for QLT.
View Industry Companies
 

Industry Analysis

QLT

Industry Average

Valuation QLT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QLT INC, please visit www.qltinc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.